Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Status and phase: Completed; Phase 1

Conditions: Lung Cancer

Treatments: Drug: topotecan hydrochloride; Radiation: radiation therapy

Study type: Interventional

Funder types: NIH

Identifiers

NCT00002537

NYU-9301

NCI-T93-0015D

NCI-2012-02487

CDR0000078480 (Registry Identifier)

Details and patient eligibility

About

Phase I trial to study the effectiveness of radiation therapy plus topotecan in treating patients who have non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy may kill more tumor cells.

Full description

OBJECTIVES:

I. Determine the maximum tolerated dose of topotecan and chest irradiation in patients with non-small cell lung cancer.

II. Determine the qualitative and quantitative toxic effects of this regimen in these patients.

III. Determine the degree of antitumor activity of this regimen in these patients.

OUTLINE: This is a dose escalation study of topotecan and thoracic radiotherapy.

Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Histologically proven non-small cell lung cancer
• Eligible for chest irradiation with 3,000 to 6,000 cGy (based upon standard radiotherapy indications)
• Measurable or evaluable disease
• Measurable disease defined as bidimensionally measurable lesion on physical exam or radiograph (CT or MRI acceptable)

PATIENT CHARACTERISTICS:

• Age: 18 and over
• Performance status: 0-2
• Life expectancy: At least 12 weeks
• WBC at least 4,000/mm3
• Platelet count at least 100,000/mm3
• Bilirubin no greater than 1.5 mg/dL
• AST less than 3 times normal
• Alkaline phosphatase less than 3 times normal
• Creatinine no greater than 1.5 mg/dL
• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

• No more than 1 prior chemotherapy regimen allowed
• At least 4 weeks since prior chemotherapy and recovered
• No prior radiotherapy
• Recovered from toxic effects of any prior therapy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Arm I

Experimental group

Description:

Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity.

Treatment:

Radiation: radiation therapy

Drug: topotecan hydrochloride